Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: The DETECT study

Breast Cancer Research

Volumn 14, Issue 4, 2012, Pages

  Müller, Volkmar ^a   Riethdorf, Sabine ^h   Rack, Brigitte ^b   Janni, Wolfgang ^c   Fasching, Peter A ^d   Solomayer, Erich ^e   Aktas, Bahriye ^f   Kasimir Bauer, Sabine ^f   Pantel, Klaus ^a   Fehm, Tanja ^g  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c University Medical Center   (Germany)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e University Medical Center   (Germany)

^f UNIVERSITY HOSPITAL ESSEN   (Germany)

^g UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^h NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR MARKER;

ADNATEST BREAST; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER PATIENT; CELL ASSAY; CELLSEARCH SYSTEM; CIRCULATING TUMOR CELL; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL PREDICTION; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST CANCER; BREAST NEOPLASMS; CLINICAL TRIAL; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; METASTASIS; MORTALITY; PATHOLOGY; PROCEDURES; PROGNOSIS; RISK; RISK FACTOR; TUMOR EMBOLISM;

BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; ODDS RATIO; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84870055312     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3243     Document Type: Article

References (28)

1. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004, 351:781-791. 10.1056/NEJMoa040766, 15317891.
2. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, Matera J, Allard WJ, Doyle GV, Terstappen LW. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 2006, 12:4218-4224. 10.1158/1078-0432.CCR-05-2821, 16857794.
3. Pantel K, Alix-Panabieres C, Riethdorf S. Cancer micrometastases. Nat Rev Clin Oncol 2009, 6:339-351. 10.1038/nrclinonc.2009.44, 19399023.
4. Müller V, Alix-Panabieres C, Pantel K. Insights into minimal residual disease in cancer patients: implications for anti-cancer therapies. Eur J Cancer 2010, 46:1189-1197. 10.1016/j.ejca.2010.02.038, 20347588.
5. Riethdorf S, Fritsche H, Müller V, Rau T, Schindlbeck C, Rack B, Janni W, Coith C, Beck K, Janicke F, Jackson S, Gornet T, Cristofanilli M, Pantel K. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch System. Clin Cancer Res 2007, 13:920-928. 10.1158/1078-0432.CCR-06-1695, 17289886.
6. Bidard FC, Vincent-Salomon A, Sigal-Zafrani B, Dieras V, Mathiot C, Mignot L, Thiery JP, Sastre-Garau X, Pierga JY. Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells. Ann Oncol 2008, 19:496-500.
7. Fehm T, Hoffmann O, Aktas B, Becker S, Solomayer EF, Wallwiener D, Kimmig R, Kasimir-Bauer S. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res 2009, 11:R59. 10.1186/bcr2349, 2750121, 19664291.
8. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res 2009, 11:R46. 10.1186/bcr2333, 2750105, 19589136.
9. Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC, Matera J, Repollet M, Doyle GV, Terstappen LW, Hayes DF. Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer. Clin Cancer Res 2006, 12:6403-6409. 10.1158/1078-0432.CCR-05-1769, 17085652.
10. Riethdorf S, Müller V, Zhang L, Rau T, Loibl S, Komor M, Roller M, Huober J, Fehm T, Schrader I, Hilfrich J, Holms F, Tesch H, Eidtmann H, Untch M, von Minckwitz G, Pantel K. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 2010, 16:2634-2645. 10.1158/1078-0432.CCR-09-2042, 20406831.
11. Hauch S, Zimmermann S, Lankiewicz S, Zieglschmid V, Bocher O, Albert WH. The clinical significance of circulating tumour cells in breast cancer and colorectal cancer patients. Anticancer Res 2007, 27:1337-1341.
12. Hayes DF, Walker TM, Singh B, Vitetta ES, Uhr JW, Gross S, Rao C, Doyle GV, Terstappen LW. Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer. Int J Oncol 2002, 21:1111-1117.
13. Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, Beitsch P, Khan A, Euhus D, Osborne C, Frenkel E, Hoover S, Leitch M, Clifford E, Vitetta E, Morrison L, Herlyn D, Terstappen LW, Fleming T, Fehm T, Tucker T, Lane N, Wang J, Uhr J. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 2004, 101:9393-9398. 10.1073/pnas.0402993101, 438987, 15194824.
14. Fehm T, Müller V, Aktas B, Janni W, Schneeweiss A, Stickeler E, Lattrich K, Löhberg C, Solomayer E, Rack B, Riethdorf S, Klein C, Schindlbeck C, Brocker K, Kasimir-Bauer S, Wallwiener D, Pantel K. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Can Res Treat 2010, 124:403-412.
15. Hayes DF, Ethier S, Lippman ME. New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK. Breast Cancer Res Treat 2006, 100:237-238. 10.1007/s10549-006-9253-5, 16773436.
16. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005, 97:1180-1184. 10.1093/jnci/dji237, 16106022.
17. Wicha MS, Hayes DF. Circulating tumor cells: not all detected cells are bad and not all bad cells are detected. J Clin Oncol 2011, 29:1508-1511. 10.1200/JCO.2010.34.0026, 21422428.
18. Thurm H, Ebel S, Kentenich C, Hemsen A, Riethdorf S, Coith C, Wallwiener D, Braun S, Oberhoff C, Janicke F, Pantel K. Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy. Clin Cancer Res 2003, 9:2598-2604.
19. Sieuwerts AM, Kraan J, Bolt J, van der Spoel P, Elstrodt F, Schutte M, Martens JW, Gratama JW, Sleijfer S, Foekens JA. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst 2009, 101:61-66. 2639293, 19116383.
20. Giordano A, Giuliano M, De Laurentiis M, Arpino G, Jackson S, Handy BC, Ueno NT, Andreopoulou E, Alvarez RH, Valero V, De Placido S, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Ann Oncol 2012, 23:1144-1150. 10.1093/annonc/mdr434, 21965473.
21. SWOG 0500: Treatment Decision Making Based on Blood Levels of Tumor Cells in Women With Metastatic Breast Cancer Receiving Chemotherapy. , http://clinicaltrials.gov/ct2/show/NCT00382018?term=SWOG+0500&rank=1
22. CirCé01: Circulating Tumor Cells to Guide Chemotherapy for Metastatic Breast Cancer. , http://clinicaltrials.gov/ct2/show/NCT01349842
23. DETECT III. , http://www.detect-studien.de/
24. Rack BK, Schindlbeck C, Andergassen U, Schneeweiss A, Zwingers T, Lichtenegger W, Beckmann M, Sommer HL, Pantel K, Janni W. Use of circulating tumor cells (CTC) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy to predict risk for relapse: The SUCCESS trial. J Clin Oncol 2010, 28. abstract 1003.
25. Van der Auwera I, Peeters D, Benoy IH, Elst HJ, Van Laere SJ, Prove A, Maes H, Huget P, van Dam P, Vermeulen PB, Dirix LY. Circulating tumour cell detection: a direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer. Br J Cancer 2010, 102:276-284. 10.1038/sj.bjc.6605472, 2816650, 19953098.
26. Tewes M, Aktas B, Welt A, Mueller S, Hauch S, Kimmig R, Kasimir-Bauer S. Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. Breast Cancer Res Treat 2009, 115:581-590. 10.1007/s10549-008-0143-x, 18679793.
27. Andreopoulou E, Yang LY, Rangel KM, Reuben JM, Hsu L, Krishnamurthy S, Valero V, Fritsche HA, Cristofanilli M. Comparison of assay methods for detection of circulating tumor cells (CTCs) in metastatic breast cancer (MBC): AdnaGen AdnaTest BreastCancer Select/Detect versus Veridex CellSearch system. Int J Cancer 2012, 130:1590-1597. 10.1002/ijc.26111, 21469140.
28. Alix-Panabieres C, Schwarzenbach H, Pantel K. Circulating tumor cells and circulating tumor DNA. Annu Rev Med 2012, 63:199-215. 10.1146/annurev-med-062310-094219, 22053740.